A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN SUBJECTS WITH NEWLY DIAGNOSED CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006820/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of
bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase
Chronic Myelogenous Leukemia (CML). The primary endpoint is cytogenetic response rate at one
year.
提供机构：
Vivli
创建时间：
2021-04-02
